Joseph K Belanoff sold $3.3M of CORT
Chief Executive Officer at CORCEPT THERAPEUTICS INC. 40,000 shares at an average of $82.86, traded Jun 2, 2025, filed Jun 4, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.3M at market
- 0Share of holdings soldSold 1.4% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-081939, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 2, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -4,881 | $78.42 | $383k | 2,937,104 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -3,050 | $79.48 | $242k | 2,934,054 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -2,988 | $80.30 | $240k | 2,931,066 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -1,820 | $81.33 | $148k | 2,929,246 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -1,263 | $82.26 | $104k | 2,927,983 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -4,631 | $83.46 | $387k | 2,923,352 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -12,959 | $84.57 | $1.1M | 2,910,393 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -8,408 | $85.01 | $715k | 2,901,985 | Jun 4, 2025 |
Related signals
Other insiders at CORCEPT THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -242% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.2M 10,000 shares | -154% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $967k 8,333 shares | -68% | |
| 20Weak | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $30k 296 shares | -7% | |
| 35Weak | CORCEPT THERAPEUTICS INC | James N Wilson director | $1.1M 10,000 shares | -1% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.1M 10,000 shares | -64% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $6.5M 58,333 shares | -93% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -72% | |
| 48Moderate | CORCEPT THERAPEUTICS INC | Gary Charles Robb Chief Business Officer | $225k 3,185 shares | -19% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | William Guyer Chief Development Officer | $1.4M 20,000 shares | -78% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.